Literature DB >> 35503486

Impact of Comorbid Psychiatric Disorders on Healthcare Utilization in Patients with Inflammatory Bowel Disease: A Nationally Representative Cohort Study.

Eddie Hill1, Nghia H Nguyen1, Alexander S Qian1, Sagar Patel1, Peter L Chen1, Chung-Sang Tse1, Siddharth Singh2.   

Abstract

BACKGROUND AND AIMS: Patients with inflammatory bowel disease (IBD) frequently experience comorbid psychiatric disorders, which negatively impact quality of life. We characterized the longitudinal burden of hospitalization-related healthcare utilization in adults with IBD with and without comorbid anxiety, depression, or bipolar disorder.
METHODS: In the 2017 Nationwide Readmissions Database (NRD), we identified 40,177 patients with IBD who were hospitalized between January 1, 2017 and June 30, 2017 and who were followed until December 31, 2017. In this cohort, we compared the annual burden (i.e., total days spent in hospital), costs, risk of readmission, inpatient mortality, and IBD-related surgery in patients with and without comorbid psychiatric disorders (anxiety, depression, or bipolar disorder).
RESULTS: Of the 40,177 adults who were hospitalized for IBD, 25.7% had comorbid psychiatric disorders. Over a 10 month-long period of follow-up, patients with comorbid psychiatric disorders spent more days in the hospital (median, 7 days vs. 5 days, p < 0.01), experienced higher 30-day (31.3 vs. 25.4%; p < 0.01) and 90-day (42.6 vs. 35.3%, p < 0.01) readmission rates, and had higher hospitalization-related costs (median, $41,418 vs. $39,242, p < 0.01). However, they were less likely to undergo IBD-related procedures or surgeries. There were no differences in risk of mortality. On Cox proportional hazard analysis, the presence of comorbid psychiatric disorders was associated with a 16% higher risk of readmission (HR, 1.16; 95% CI, 1.13-1.20) and a 13% higher risk of severe IBD-related hospitalization (HR, 1.13; 95% CI, 1.08-1.16).
CONCLUSIONS: In adults with IBD, comorbid psychiatric disorders were independently associated with a higher burden and cost of hospitalization, without an increase in the risk of IBD-related surgery or procedures. Population-based interventions aimed at treating psychiatric comorbidities may decrease the risk of unplanned healthcare utilization.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anxiety; Bipolar disorder; Crohn’s disease; Depression; Hospitalization

Mesh:

Year:  2022        PMID: 35503486     DOI: 10.1007/s10620-022-07505-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.487


  33 in total

1.  Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.

Authors:  Brigida Barberio; Mohammad Zamani; Christopher J Black; Edoardo V Savarino; Alexander C Ford
Journal:  Lancet Gastroenterol Hepatol       Date:  2021-03-12

2.  Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health.

Authors:  Forough Farrokhyar; John K Marshall; Brock Easterbrook; E Jan Irvine
Journal:  Inflamm Bowel Dis       Date:  2006-01       Impact factor: 5.325

3.  Psychiatric predictors of noncompliance in inflammatory bowel disease: psychiatry and compliance.

Authors:  G Nigro; G Angelini; S B Grosso; G Caula; C Sategna-Guidetti
Journal:  J Clin Gastroenterol       Date:  2001-01       Impact factor: 3.062

4.  Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease.

Authors:  Casandra Dolovich; Charles N Bernstein; Harminder Singh; Zoann Nugent; Aruni Tennakoon; Leigh Ann Shafer; Ruth Ann Marrie; Jitender Sareen; Laura E Targownik
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-12       Impact factor: 11.382

Review 5.  Depression and anxiety in patients with Inflammatory Bowel Disease: A systematic review.

Authors:  Rachel Neuendorf; Aubrey Harding; Noelle Stello; Douglas Hanes; Helané Wahbeh
Journal:  J Psychosom Res       Date:  2016-06-06       Impact factor: 3.006

6.  Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease.

Authors:  Mirjam Severs; Marie-Josée J Mangen; Herma H Fidder; Mirthe E van der Valk; Mike van der Have; Ad A van Bodegraven; Cees H M Clemens; Gerard Dijkstra; Jeroen M Jansen; Dirk J de Jong; Nofel Mahmmod; Paul C van de Meeberg; Andrea E van der Meulen-de Jong; Marieke Pierik; Cyriel Y Ponsioen; Marielle J L Romberg-Camps; Peter D Siersema; Bindia Jharap; Janneke C van der Woude; Nicolaas P A Zuithoff; Bas Oldenburg
Journal:  Inflamm Bowel Dis       Date:  2017-09       Impact factor: 5.325

Review 7.  Global prevalence of anxiety disorders: a systematic review and meta-regression.

Authors:  A J Baxter; K M Scott; T Vos; H A Whiteford
Journal:  Psychol Med       Date:  2012-07-10       Impact factor: 7.723

8.  The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease.

Authors:  Laura E Targownik; Eric I Benchimol; Julia Witt; Charles N Bernstein; Harminder Singh; Lisa Lix; Aruni Tennakoon; Antonio Aviña Zubieta; Stephanie Coward; Jennifer Jones; Ellen Kuenzig; Sanjay K Murthy; Geoffrey C Nguyen; Juan Nicolás Peña-Sánchez; Gil Kaplan
Journal:  Inflamm Bowel Dis       Date:  2019-09-18       Impact factor: 5.325

9.  Depressive Symptoms Predict Anti-tumor Necrosis Factor Therapy Noncompliance in Patients with Inflammatory Bowel Disease.

Authors:  Alexis Calloway; Robin Dalal; Dawn B Beaulieu; Caroline Duley; Kimberly Annis; Lawrence Gaines; Chris Slaughter; David A Schwartz; Sara Horst
Journal:  Dig Dis Sci       Date:  2017-10-20       Impact factor: 3.199

10.  The influence of depression on quality of life in patients with inflammatory bowel disease.

Authors:  Clarence K Zhang; Jennifer Hewett; Jason Hemming; Taneisha Grant; Hongyu Zhao; Clara Abraham; Ioannis Oikonomou; Meera Kanakia; Judy H Cho; Deborah D Proctor
Journal:  Inflamm Bowel Dis       Date:  2013-07       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.